DelveInsight’s ‘Ulcerative Colitis Pipeline Insight 2023‘ report provides comprehensive global coverage of available, marketed, and pipeline Ulcerative Colitis therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Ulcerative Colitis pipeline domain.
Key Takeaways from the Ulcerative Colitis Pipeline Report
- Over 110+ Ulcerative Colitis pipeline therapies are in various stages of development, and their anticipated acceptance in the Ulcerative Colitis market would significantly increase market revenue.
- Leading Ulcerative Colitis companies developing novel drug candidates to improve the Ulcerative Colitis treatment landscape include Eli Lilly and Company, AbbVie, Pfizer, and others.
- Promising Ulcerative Colitis pipeline therapies in various stages of development include Mirikizumab, Risankizumab, Etrasimod, and others.
Ulcerative Colitis Overview
Ulcerative colitis is a chronic disease of the large intestine, in which the lining of the colon become inflamed and develops tiny open sores or ulcers. Those ulcers produce pus and mucous, which causes abdominal pain. It usually begins in the rectum and spreads upwards. The inflammation causes bowel to move its content rapidly and empty frequently. Ulcerative colitis begins gradually and become worse over the period of time. Ulcerative colitis also known as inflammatory bowel disease. Ulcerative colitis symptoms range from mild to severe and varies among affected people. The predominant symptoms in ulcerative colitis is diarrhea, which can be associated with the discharge of blood in the stool.
Ulcerative Colitis Pipeline Analysis: Drug Profile
Mirikizumab: Eli Lilly and Company
Mirikizumab is a humanized IgG4 monoclonal antibody that binds to the p19 subunit of interleukin 23. Mirikizumab is being studied for the treatment of immune-mediated diseases, including ulcerative colitis and Crohn’s disease.
Discover more about the emerging Ulcerative Colitis drugs @ Ulcerative Colitis Treatment Drugs
Ulcerative Colitis Key Companies
- Eli Lilly and Company
- AbbVie
- Pfizer
Ulcerative Colitis Pipeline Therapies
- Mirikizumab
- Risankizumab
- Etrasimod
Ulcerative Colitis Pipeline Therapeutics Assessment
- By development stage
- By product type
- By route of administration
- By molecule type
- By MOA type
Scope of the Ulcerative Colitis Pipeline Report
- Coverage: Global
- Key Ulcerative Colitis Companies: Eli Lilly and Company, AbbVie, Pfizer, and others
- Key Ulcerative Colitis Pipeline Therapies: Mirikizumab, Risankizumab, Etrasimod, and others
Find out more about the Ulcerative Colitis treatment options in development @ Ulcerative Colitis Clinical Trials
Table of Contents
1. Introduction
2. Executive Summary
3. Overview
4. Pipeline Therapeutics
5. Late-Stage Products (Phase III)
6. Mid-Stage Products (Phase II)
7. Early Stage Products (Phase I/II)
8. Preclinical Stage Products
9. Discovery Stage Products
10. Therapeutic Assessment
11. Inactive Products
12. Collaborations Assessment- Licensing / Partnering / Funding
13. Unmet Needs
14. Market Drivers and Barriers
15. Appendix
16. About DelveInsight
Other Trending Reports:
- Asthma Diagnostic Devices Market
- Chronic Obstructive Pulmonary Disease Treatment Devices Market
- Airway Management Devices Market
- Cough Assist Devices Market
- Pulse Oximeters Market
- Hemodialysis Catheter Devices Market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences.
Contact Us
Kritika Rehani
info@delveinsight.com
+1(919)321-6187
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/